Athanor Capital, LP Protagonist Therapeutics, Inc Transaction History

Athanor Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $223,686 - $392,610	-8,748 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$19.02 - $31.15 $128,917 - $211,134	-6,778 Reduced 43.66%	8,748 $227,000
Q4 2020 Feb 16, 2021	SELL	$18.49 - $25.13 $2,255 - $3,065	-122 Reduced 0.78%	15,526 $313,000
Q3 2020 Nov 16, 2020	BUY	$15.19 - $22.4 $237,693 - $350,515	15,648 New	15,648 $306,000

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.28B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.